Dr. Reetika, R14008, Dr.Lalit Kumar Tejwani, Dr. Himanshu Shekhar
Purpose: To study the efficacy of trabeculectomy with MMC combined with anti-VEGF augmented Ologen in cases with high risk for failure.
Methods: Three eyes of 3 patients who had high risk for failure underwent trabeculectomy with subconjunctival and subscleral MMC application combined with Ologen implantation subconjunctivally and subsclerally. The subconjunctival Ologen was wet with 0.1 ml Bevacizumab.
Results: All the eyes achieved target IOP, which was maintained until six months of follow-up.
Conclusions: VEGF concentration has been seen to increase in the aqueous humor after filtration surgery. Ologen implantation helps in collagen remodelling, antifibroblastic response and acts as a spacer. Bevacizumab augmented Ologen, in addition, targets the increased VEGF and helps in decreasing scarring. Anti-VEGF augmented Ologen in trabeculectomy with MMC hence appears to have encouraging short-term intraocular pressure control and may be adopted in eyes with risk factors for failure.